Allogene Therapeutics (NASDAQ:ALLO) Announces Earnings Results

Allogene Therapeutics (NASDAQ:ALLO) released its quarterly earnings data on Thursday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Stock Performance

NASDAQ:ALLO opened at $1.94 on Friday. The stock has a market capitalization of $406.76 million, a P/E ratio of -1.24 and a beta of 1.02. The company has a 50 day moving average price of $1.94 and a 200 day moving average price of $2.32. Allogene Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $4.89.

Insider Buying and Selling

In related news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares of the company’s stock, valued at approximately $428,719.23. This trade represents a 5.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,710 shares of company stock valued at $92,125. Company insiders own 24.30% of the company’s stock.

Wall Street Analyst Weigh In

ALLO has been the subject of a number of recent research reports. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a report on Friday. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Allogene Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $9.40.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).